Efficacy at 52 weeks of daily clinical use of iguratimod in patients with rheumatoid arthritis

Abstract Objective. In recent years, the use of one or more conventional synthetic disease-modifying antirheumatic drugs has been recommended for the treatment of rheumatoid arthritis (RA). We performed a 52-week study on the efficacy and safety of iguratimod (IGU) against patients with RA in daily...

Full description

Saved in:
Bibliographic Details
Published in:Modern rheumatology 2015-07, Vol.25 (4), p.534-539
Main Authors: Okamura, Koichi, Yonemoto, Yukio, Suto, Takahito, Okura, Chisa, Takagishi, Kenji
Format: Article
Language:English
Subjects:
Aged
Aged, 80 and over
Arthritis, Rheumatoid - blood
Arthritis, Rheumatoid - drug therapy
Blood Sedimentation
C-Reactive Protein - metabolism
Chromones - administration & dosage
Disease-modifying antirheumatic drugs
Dose-Response Relationship, Drug
Drug Administration Schedule
Female
Follow-Up Studies
Humans
Iguratimod
Male
Matrix metalloproteinase-3
Medical treatment
Methotrexate
Middle Aged
Pneumonia
Proteins
Retrospective Studies
Rheumatoid arthritis
Rheumatology
Sulfonamides - administration & dosage
Time Factors
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Objective. In recent years, the use of one or more conventional synthetic disease-modifying antirheumatic drugs has been recommended for the treatment of rheumatoid arthritis (RA). We performed a 52-week study on the efficacy and safety of iguratimod (IGU) against patients with RA in daily clinical use. Methods. Forty-one patients were enrolled in this study, and the clinical course of RA was regularly evaluated during the 52 weeks of treatment. Results. The survival rate at week 52 was 53.7%. The disease activity score (DAS) 28-erythrocyte sedimentation rate, DAS28-C-reactive protein, simplified disease activity index, and clinical disease activity index were all significantly decreased at week 52. The matrix metalloproteinase-3 level was significantly decreased at week 52 by combination therapy of IGU and methotrexate. There were one case of the onset of interstitial pneumonia (IP), one exacerbation of IP, and one case of the onset of Pneumocystis jiroveci pneumonia. Conclusions. IGU is effective for RA patients when used for daily clinical treatment for 52 weeks.
ISSN:1439-7595
1439-7609
DOI:10.3109/14397595.2014.998361